SCHEMBL732918

SCHEMBL732918

Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)c3cc(-c4nnn[nH]4)cc(N4CCCC4)c3)CC1)O2

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.51
CACNA1C Q13936 2/20 0.51
CYP2C9 P11712 1/20 0.51
ACACB O00763 11/20 0.41
ACACA Q13085 1/20 0.40
HDAC3 O15379 3/20 0.39
HDAC4 P56524 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC7 Q8WUI4 3/20 0.39
HDAC2 Q92769 3/20 0.39
HDAC10 Q969S8 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
HDAC8 Q9BY41 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
HDAC9 Q9UKV0 3/20 0.39
HDAC5 Q9UQL6 3/20 0.39
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741033 0.89 EPHX2 (0.51) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL15163403 0.87 CYP2C9 (0.50) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL733043 0.87 CYP2C9 (0.49) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL733042 0.87 CYP2C9 (0.49) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL730331 0.84 EPHX2 (0.56) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL733069 0.81 EPHX2 (0.49) EPHX2CACNA1CCYP2C9ACACBACACA
SCHEMBL742027 0.81 ACACB (0.45) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL15163380 0.79 ACACB (0.46) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL731146 0.78 ACACB (0.45) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL731147 0.78 ACACB (0.45) ACACBACACAHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP claimed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US claimed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US claimed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 EPHX2 2301/4885CACNA1C 2444/4885CYP2C9 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.